NEWS

News2020-03-07T14:18:44+01:00

LTS announces the appointment of David Doles as new President and Chief Executive Officer for its US affiliate LTS Corp.

16.12.2019|Company News|

LTS Lohmann Therapie-Systeme AG, the market leader for the development and manufacturing of transdermal therapeutic systems, is very pleased to announce the appointment of Mr. David Doles as the President and Chief Executive Officer for its US affiliate, LTS Lohmann Therapy Systems, Corp. effective 1 January 2020.

LEO Pharma A/S and LTS Lohmann Therapie-Systeme AG initiate first-ever clinical trial of microarray patches for psoriasis treatment

19.03.2019|Press Releases|

LTS Lohmann Therapie-Systeme AG (LTS), a market leader in transdermal therapeutic systems, and LEO Pharma A/S, a global leader in dermatology, today announced that the companies will start the clinical trial of microarray patches for the local intradermal treatment of psoriasis.

LTS AG donates a new pediatric anaesthesia trolley to the St. Nikolaus-Stifts Hospital in Andernach.

4.02.2019|Press Releases|

In January members of the Association, along with Dr. Torsten Baehner, head physician of the Anaesthesia and IC unit at St. Nikolaus-Stift Hospital, displayed the trolley for Ulrich Sielaff, member of the board at LTS.

Intec Pharma Partners with LTS for Manufacture of Accordion Pill Carbidopa/Levodopa for Treatment of Parkinson’s Disease

12.03.2018|Company News|

Initial results of the market analysis indicate there is a substantial market for AP-CD/LD to potentially serve hundreds of thousands of patients suffering with Parkinson's Disease.